Previous 10 | Next 10 |
home / stock / zldpf / zldpf news
Press release - No. 9/2018 Zealand and Roche Diabetes Care enter Phase 3 study collaboration for treatment of congenital hyperinsulinism with dasiglucagon Zealand has entered a collaboration agreement with Roche Diabetes Care to use its Accu-Chek ® Combo ...
Company Announcement - No. 10/2018 Zealand Pharma convenes its Annual General Meeting 2018 For further information, please contact: Britt Meelby Jensen , President and CEO Tel.: +45 51 67 61 28, e-mail: bmj@zealandpharma.com Mats Blom , Executive Vice President and ...
Press release - No. 07 / 2018 Zealand Pharma to present at the Needham Healthcare Conference, March 27, 2018 in New York Copenhagen, March 22, 2018 - Britt Meelby Jensen, President and Chief Executive Officer (CEO) of Zealand Pharma, will present at the 17 th Annual Needham H...
A Phase 3 clinical trial assessing the safety, tolerability and immunogenicity of Zealand Pharma A/S's ( OTCPK:ZLDPF ) dasiglucagon in type 1 diabetics met the primary and key secondary endpoints. More news on: Zealand Pharma A/S, Healthcare stocks news, Read more ...
Company Announcement - No. 9/2018 Zealand Pharma's first Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia successfully meets its primary objective Results confirm dasiglucagon's safety profile with no treatment-induced or treatment-boosted anti-drug antibodie...
Zealand Pharma ( OTCPK:ZLDPF ): FY net loss of $43.9M More news on: Zealand Pharma A/S, Earnings news and commentary, Read more ...
Company announcement - No. 8 / 2018 Zealand Pharma 2017 full-year results in line with guidance - considerable progress in the clinical portfolio Copenhagen, March 7, 2018 - Zealand Pharma A/S ("Zealand") (CVR No. 20 04 50 78) announces financial results in line with ...
Company announcement - No. 7/2018 Zealand reports royalty revenue for the fourth quarter of 2017 Zealand reports royalty revenue of DKK 11.3 million/USD 1.8 million for Q4 2017 The revenue is based on total net sales of Lyxumia ® /Adlyxin ® and Soliqua ® 100...
Healthcare investors have a full slate of events ahead next week: More news on: Roche Holding Ltd ADR, BioTime, Inc, Anavex Life Sciences Corp., Healthcare stocks news, Read more ...
Press release - No. 2/2017 Zealand Pharma hosts Capital Market Day: Accelerating the late stage pipeline Four late stage programs with best-in-class potential and attractive risk profiles...
News, Short Squeeze, Breakout and More Instantly...
Zealand Pharma A/S Ord Company Name:
ZLDPF Stock Symbol:
OTCMKTS Market:
Zealand Pharma A/S Ord Website:
Company announcement – No. 35 / 2024 Zealand Pharma announces completion of an upsized equity offering of 8.35 million new ordinary shares raising gross proceeds of USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE U...
Company announcement – No. 34 / 2024 Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO T...
Company announcement – No. 33 / 2024 Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CAN...